Drugmaker Pfizer topped off a difficult third quarter with news that it’s scrapping a closely watched experimental cholesterol drug, partly due to expectations insurers would limit access so much that it wouldn’t make much money, a possible bad omen for the pharmaceutical industry. The biggest U.S.-based drugmaker on Tuesday reported its quarterly profit plunged 38
